Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.

This is a prospective study designed to evaluate the efficacy and safety of Teprotumumab N01 in patients with Thyroid Eye Disease (TED). Eligible patients will receive Teprotumumab N01 and will be assessed using clinical and imaging parameters before and after treatment, with each patient serving as their own control. The primary endpoint is the overall response rate at Week 24.

NCT Number	NCT07423013
Lead Sponsor	Peking University Third Hospital Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions	Thyroid Eye Disease
Enrollment	50 participants
Start Date	2025-11-11
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-20